Expression of PD-L1 in the tumor microenvironment is thought to be crucial for therapeutic activity6; however, further investigations suggest that the expression of PD-L1 is not an ideal biomarker since the PD-L1 expression assessed by immunohistochemistry and the associated response to immune checkpoint inhibitors are not always concordant7, 8. Here, CD274 is linked to neoplasm.